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KEBERKESANAN KOS KLINIK KEPATUHAN TERAPI WARFARIN  
BERBANDING KLINIK PERUBATAN BIASA DI  
HOSPITAL KUALA LUMPUR 
 
ABSTRAK 
Rawatan antikoagulasi secara sistematik disyorkan dalam pengurusan pesakit 
yang menggunakan rawatan warfarin secara kronik. Perkhidmatan seperti ini baru 
diperkenalkan di Malaysia dan dikenali sebagai Klinik Kepatuhan Terapi Warfarin 
(WMTAC) dimana ia dikendalikan oleh ahli farmasi dengan nasihat pakar perubatan. 
Objektif kajian ini ialah untuk menilai keberkesanan kos rawatan antikoagulasi 
sistematik berbanding klinik perubatan sedia ada (UMC) yang dikendalikan oleh 
pegawai perubatan di Hospital Kuala Lumpur (KLH), hospital kerajaan bagi        
rujukan rawatan tertiari. Satu kajian kohort retrospektif selama enam bulan dilakukan 
untuk membandingkan kedua-dua jenis model rawatan ini. Satu pesampelan rawak 
digunakan untuk mengenalpasti 92 pesakit dari setiap klinik. Min peratusan masa di 
dalam julat terapeutik (TTR) bagi International Normalized Ratio (INR) bagi pesakit 
yang  disyorkan dalam Garispanduan Praktis Klinikal di Malaysia bagi pencegahan dan 
rawatan Venous Thromboembolism bagi tahun 2013 digunakan untuk menilai 
keberkesanan klinik. Kos min rawatan setiap klinik merangkumi empat aktiviti          
kos, iaitu kos pemantauan, masa perundingan klinik dan pendispensan, ubat dan 
peristiwa mudarat. Kos dianggarkan mengunakan kajian masa-pergerakan bagi           
INR di dalam dan di luar julat terapeutik. Satu model Markov yang berkitaran enam 
bulan dari perspektif penyedia perkhidmatan digunakan untuk mensimulasikan 
keberkesanan kos seumur hayat. Kes asas model berbatasan masa selama 20 tahun 
dengan keberkesanan kos yang berandaian kohort pesakit dengan AF berumur 57 tahun 
xii 
 
dengan penyakit komorbid.  Kebarangkalian peralihan untuk hasil klinik diperolehi   
dari carian jurnal. Andaian model yang digunakan ialah kebarangkalian kesan yang 
sama antara klinik dan antara kitaran. Kos dan keberkesanan masa hadapan 
menggunakan diskaun 3% untuk ditukarkan ke nilai semasa.  Semua kos berdasarkan 
Ringgit Malaysia (MYR) tahun 2007. Peratusan masa dalam julat terapeutik (TTR) lebih 
tinggi secara signifikan di WMTAC berbanding UMC (66.1% berbanding, 48.3%; p < 
0.001). Perbezaaan kos min enam    bulan juga signifikan (p < 0.001), dimana kos UMC 
dan WMTAC ialah MYR 537.38 (SD = 352.39) dan MYR 352.62 (SD = 180.21) 
masing-masing. Keputusan model jangkamasa 20 tahun menunjukan kos min WMTAC 
ialah MYR 5864.10, manakala   kos min UMC ialah MYR 6550.96 bagi jangkamasa 
hayat selama 6.15 dan 6.17      tahun bagi UMC dan WMTAC. UMC didominasi oleh 
WMTAC bagi kedua-dua    jangkamasa analisa, enam bulan dan seumur hayat. Analisa 
kepekaan model menunjukkan bahawa kos klinik mempengaruhi keberkesanan kos. 
Sekiranya kos WMTAC meningkat melebihi 50% atau kos UMC menurun melebihi 
25%, WMTAC tidak menjadi intervensi yang dominan. Secara kesimpulannya, 
perkhidmatan WMTAC lebih kos-efektif  berbanding  UMC     di KLH. WMTAC lebih 
kos efektif, kerana dapat meningkatkan peratusan jangkamasa dalam julat terapeutik dan 
mengurangkan kekerapan lawatan klinik dan kemasukan ke wad. Pengekalan peratusan 
jangkamasa dalam julat terapeutik melebihi 70%, iaitu masa piawai adalah penting 
untuk memastikan keberkesanan kosnya.  
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COST-EFFECTIVENESS OF WARFARIN MEDICATION THERAPY 
ADHERENCE CLINIC VERSUS USUAL MEDICAL CLINIC AT KUALA 
LUMPUR HOSPITAL 
 
ABSTRACT 
Systematic anticoagulation management clinic is now recommended to manage 
atrial fibrillation (AF) patients on chronic warfarin therapy. In Malaysia, the service is 
recently introduced as pharmacist managed Warfarin Medication Therapy Adherence 
Clinic (WMTAC) which is managed by the pharmacist with a physician advisory. The 
objective of the present study was to assess the cost effectiveness of anticoagulation 
clinic in comparison to usual medical clinic (UMC) which is managed by medical 
officers in Kuala Lumpur Hospital (KLH), a tertiary referral hospital in Malaysia. A six 
month retrospective cohort study comparing the two anticoagulation    management 
models was conducted. Systematic random sampling was used to sample   a total of 92 
patients from each clinic. The mean percentages of time within therapeutic range (TTR) 
for the patients which is recommended in the 2013 Malaysian Clinical Practice 
Guidelines on the Prevention and Treatment of Venous Thromboembolism were used as 
effectiveness. The mean total cost of each clinic included four cost activities such as the 
cost of monitoring, clinic consultation and dispensing, drug and adverse event.  The 
costs were estimated using the time-motion study for the INR within and outside the 
therapeutic range. A six monthly cycle Markov model from the provider perspective was 
used to simulate life time cost effectiveness. The base case analysis assumed a cohort of 
patients with AF, 57 years of age with comorbid illnesses. The transition probabilities of 
these clinics outcomes were obtained from a literature search. The model assumptions 
were that  the outcomes probabilities were similar for both the clinics and between the 
xiv 
 
cycles. Future costs and effectiveness were discounted 3% to convert to present values. 
All   costs were in Malaysian Ringgit (MYR) based on year 2007. Percentage of time in 
therapeutic range (TTR) was also significantly higher in   WMTAC than those in UMC 
(66.1% vs. 48.3%; p < 0.001). Mean six months   treatment cost was MYR 537.38 (SD 
= 352.39) for UMC and MYR 352.62 (SD = 180.21) for WMTAC, which was 
significantly higher (p < 0.001). Results of a 20-year period model showed that the mean 
cost of the WMTAC was MYR 5864.10 whereas the UMC cost was MYR 6550.96 and 
the life-years to be 6.15 and 6.17 years for UMC and WMTAC respectively. UMC was 
found to be dominated by the WMTAC for both intermediate and lifetime analysis. The 
sensitivity analysis showed that clinic treatment costs had a major impact on the cost-
effectiveness analysis. If the cost of WMTAC increased by 50% or if the UMC cost 
dropped more than 25% of the current cost, the WMTAC would not be a dominant 
intervention. In conclusion, WMTAC is a more cost effective option than UMC in KLH. 
The WMTAC is cost-effective, as it is able to improve the percentage of time within 
therapeutic range and reduce the frequency of clinics visits and ward admissions. 
Maintaining the TTR above the gold standard of 70%, is important to ensure                
its’ effectiveness. 
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CHAPTER 1:  INTRODUCTION 
The incidence of Venous Thromboembolism Embolism (VTE) is increasing globally. 
The worldwide incidence exceeds 1 per 1000 (Ministry of Health Malaysia, 2003b, 
Nordstrom et al., 1992). VTE is a general term used to describe the blockage of a    
blood   vessel by a blood clot. VTE is often a silent disease and the first appearance    
can be fatal. Diagnosing and treating VTE patients in the United States with 
anticoagulants costs United States Dollars (USD) 3.2 to 15.5 billion per year (Cundiff, 
2004),  whereas in Europe, the total direct costs of all VTE events were estimated at 
USD 3.99 billion each year (Coalition to Prevent VTE, 2012). Vitamin K antagonist 
(VKA) is the commonly prescribed anticoagulant, as it is effective in preventing and 
treating arterial and  venous thrombosis (Geerts et al., 2001, Hyers et al., 2001, Albers et 
al., 2001, Stein et al., 2001, Cairns et al., 2001). Successful anticoagulant management 
requires careful monitoring of the International Normalized Ratio (INR), patient 
education and good communication between patients and their caregivers. Many of   the 
patients on warfarin are elderly and require assistance from family or friends or 
caregivers to manage the  monitoring and medication administration (Schulman et al., 
2010). Communication with care givers are important, as 30% of the patients are 
accompanied by a family member for clinic based testing (Lafata et al., 2000). Careful 
monitoring of INR is important as it is affected by many factors such as genetics, drugs 
and environmental factors. In addition to this, dietary vitamin K  intake, physical        
activity and adherence to therapy are also known  to affect the stability of INR    (Ageno 
et al., 2012). Quality of anticoagulant therapy has  proven to influence the risk of 
undesirable outcomes among these patients (Wilson et al., 2003). A strong relationship 
between percentage of Time in Therapeutic Range (TTR) for the INR and the rates of 
bleeding or thromboembolic events has been observed across studies with           
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different patient populations, target ranges, scales for measuring intensity of 
anticoagulation, methods of measuring TTR and  different  models of  dose management 
(Ageno et al., 2012). 
Studies have indicated that anticoagulation management and outcomes across different 
health care systems in different countries, showed an array of management styles and 
outcomes related to the model of anticoagulation care (Ansell et al., 2007a). The 
primary models of anticoagulant care are usual medical clinic, nurse, pharmacist or 
physician-managed oral anticoagulation clinic and patient self-management  (Wilson et 
al., 2003). Poor quality of dose management in routine clinical practice or usual medical 
clinic is an obstacle to the safety and effectiveness of warfarin therapy (Ageno et al., 
2012). Evidence suggests  that  the rigorous provision of follow-up care by 
anticoagulation clinic  models are more likely to attain the desired patient outcomes and 
reduce costs per person-year of follow-up than usual medical care (Wilson et al., 2003, 
Chamberlain et al., 2001). Despite evidence that the introduction of organized 
anticoagulation clinics may prevent complications, the introduction of such clinics      
has been relatively slow and the cost effectiveness of the different monitoring 
alternatives remains unknown (Lafata et al., 2000). The systematic pharmacist managed 
anticoagulation clinic model was introduced as Warfarin Medication Therapy 
Adherence Clinic (WMTAC) in Malaysia in 2005. However systematic    
anticoagulation model or WMTAC is not the primary treatment model in Malaysia. 
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1.1 Thromboembolism 
Thromboembolism (TE) is a major health problem, where it is the third most      
common cardiovascular disease after myocardial infarction and stroke (Naess et al., 
2007). The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 clearly   
document the major impact of arterial thrombosis on the global disease burden,   
because it is the pathologic mechanism of most underlying cases of ischemic heart 
disease and ischemic stroke. A systematic review of global burden of disease 
attributable to VTE identified the incidence as 0.75 to 2.69 per thousand individual       
in the population. Though the annual incidence rates in the Asian populations are 
reported to be lower, studies have demonstrated that the disease burden is not low      
due to population aging and increased life expectancy. Recent studies have 
demonstrated that the rates of VTE after major surgery and in hospitalized           
medical patients are approaching western population rates (Raskob et al., 2014).                    
In Malaysia, obstetric VTE is now the leading cause of maternal death               
(Ministry of Health Malaysia, 2013a). Initially perceived as rare in Asia, the              
VTE incidences approach values close to incidences in western countries. About 10% 
would die within the first month of diagnosis. Thus VTE is considered a          
worldwide health crisis (Naess et al., 2007, Ministry of Health Malaysia, 2013a) .  
 
1.1.1 Venous Thromboembolism (VTE) 
VTE is an important cause of death in hospitals. Treatment of VTE and its’ related   
long term morbidities are associated with considerable health service cost. VTE   
includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). Three   
major pathophysiologic determinants of VTE are venous stasis, endothelial injury and 
hypercoagulability. All risk factors for VTE influence at least one of these three    
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mechanisms (Nicolaides et al., 1971, Kakkar et al., 1969, Kumar et al., 2010). 
Complications of VTE include post-thrombotic syndrome and chronic thromboembolic 
pulmonary hypertension. Adjusted-dose VKAs are historically the primary agent used to  
effectively reduce VTE and its’ consequences (Geerts et al., 2004, National Institute for 
Health and Clinical Excellence, 2012). There is substantial evidence that venous 
thromboembolism after stroke is also a significant problem in Asia with prevalence 
ranging from 0.5 – 45 % (Tan et al., 2008). Without treatment, 50% of patients with 
symptomatic proximal DVT or PE are likely to have recurrent thrombosis within the 
first three months of diagnosis (Ribeiro et al., 1999, Dalen et al., 1997). Ten percent of 
symptomatic PE is fatal within one hour of onset of symptoms (Paraskos et al., 1973, 
Laporte et al., 2008). As for PE, 50% resolution occurs after two to four  weeks of 
treatment (Dalen et al., 1997), whereas complete resolution of    PE occurs in about two 
thirds of patients (Paraskos et al., 1973, Riedel et al., 1982, Torbicki et al., 2008). 
Resolution of proximal DVT is slow and less than half have complete lysis after six 
months of anticoagulation (Holmstrom et al., 1997). The risk of recurrence upon 
cessation    of anticoagulation is similar following proximal DVT and PE  (Douketis et 
al., 1998, Heit et al., 2000). However, the risk of mortality is two to three folds higher 
with recurrent PE. The risk of recurrent VTE is higher in unprovoked VTE or with 
persisting risk factors for thrombosis compared to  patients  with  transient risk  factors 
(e.g. recent surgery) (Prandoni et al., 1996, Research Committee of the British Thoracic 
Society, 1992, Levine et al., 2002, Kearon, 2004, Galioto et al., 2011). Mechanical 
prophylaxis is used for patients who are ineligible for pharmacologic therapy but is less 
efficacious than pharmacologic methods when used alone   (Sachdeva et al., 2010, Agu 
et al., 1999, Kearon and O'Donnell, 2010). Pharmacological prophylaxis includes low 
molecular weight  heparin (LMWH), pentasaccharide  sodium (fondaparinux), 
5 
 
unfractionated heparin (UFH) and  the     newer anticoagulants (dabigatran, rivaroxaban, 
apixaban) (Geerts et al., 2004, Kahn et al., 2012). Maintenance    treatment of VTE with 
anticoagulation is recommended, following  initial  heparinisation or fondaprinux 
treatment in patients with VTE (Ministry of Health Malaysia, 2013a). 
 
1.1.2 Atrial fibrillation (AF) 
Vascular diseases has been found to increase the risk of AF and AF has likewise been 
shown to be a major risk factor for vascular disease and cardiovascular death. Both  
VTE and AF share a number of risk factors such as increasing age, obesity, diabetes, 
heart failure and hypertension (Olesen et al., 2012).  
Atrial fibrillation is an atrial tachyarrhythmia characterized by uncoordinated           
atrial activation with consequent deterioration of  atrial  mechanical function (Ministry 
of Health Malaysia, 2012a). The five types of recognized AF are initial event, 
paroxysmal, persistent, long  standing  persistent  and  permanent (Camm et al., 2010). 
AF    is a naturally progressive disease except for a small proportion of patients who  are    
free of AF promoting conditions, who may remain in paroxysmal AF over             
several decades (Jahangir et al., 2007). AF is the most common sustained cardiac   
arrhythmia, though local data is scarce. Data from western populations estimated        
the prevalence of AF as 0.4 to 1% in the general populations. The prevalence of          
AF doubles with each decade of age, whereas the mortality rate is about double of 
patients in sinus rhythm (Ministry of Health Malaysia, 2012a).   
AF is associated with a pro-thrombotic state, intra-atrial stasis, structural heart      
disease or blood vessel abnormalities and abnormal platelets haemostasis, which 
predisposes patients to thrombus formation. This condition leads to stroke and 
thromboembolism. Antithrombotic therapy has proven to be the only method to     
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reduce AF-related mortality (Hylek et al., 2003). The CHADS2 (Congestive heart 
failure, hypertension, age = 75 years, diabetes mellitus, stroke) risk stratification scheme 
is   used to assess stroke risk, where oral anticoagulation therapy is initiated if the score   
is ≥ 2. A meta-analysis showed that adjusted-dose oral anticoagulation therapy lead to a 
significant 64% risk reduction of stroke and 26% reduction of   all-cause mortality in 
patients with non-valvular AF (Hart et al., 2007).   In addition   to the cost for treatment 
per admission of MYR 9,000 in tertiary Malaysian education  hospital, acute major 
stroke also lead to at least 10 to 15 clinic visits in the first  six months for rehabilitation 
(Aznida et al., 2012). AF increases the risk of stroke, which is a leading cause of death 
and disability worldwide. The appropriate use of oral anticoagulation in this moderate to 
high risk of stroke population, improves health outcomes (Steinberg and Piccini, 2014). 
 
1.2 Anticoagulation Therapy - Vitamin K Antagonists 
Warfarin remains the predominant anticoagulant used in Malaysia (Omar et al., 2011). 
However, there are other available VKAs worldwide such as acenocoumarol, 
phenprocoumon and fluindione. VKAs have been consistently shown to be highly 
effective in many settings and are now used by millions of patients’ worldwide.      
VKAs produce their anticoagulant effect by interfering with the cyclic interconversion 
of vitamin K and its’ epoxide. This leads to the reduction of four vitamin K      
dependant coagulation factors (Ageno et al., 2012). 
Warfarin has become the most widely used oral anticoagulant since its            
introduction in 1954. The most  common indications for  warfarin  anticoagulation      
are atrial fibrillation (AF), mechanical heart valve (MHV) and venous  
thromboembolism (Ministry of Health Malaysia, 2013a). Due to its pharmacokinetic   
and pharmacodynamics complexities, the management of warfarin therapy to         
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obtain an optimal outcome is a great challenge (Garabedian-Ruffalo et al., 1985, Wilson 
et al., 2003). Multiple factors have been shown to affect anticoagulation control, such   
as warfarin dosage, warfarin dosage preparation, drug or food interactions, patient 
compliance, patient knowledge, the setting of anticoagulation services  (Saokaew et al., 
2010) and the genetic and environmental factors (Ageno et al., 2012). Higher doses are 
needed  in warfarin resistant patients, who have genetic mutations in the gene coding        
(Ageno et al., 2012). Warfarin is also highly susceptible to drug-  drug interactions, 
where it   is known to interact with more than 200 agents (Coumadin Package Insert, 
2007). Nutritional supplements and herbal products are particularly known to be 
problematic, which patients often fail to inform physician and the physicians rarely ask   
(Wittkowsky et al., 2007). A number of medical conditions are also known to influence 
anticoagulation with warfarin (Ageno et al., 2012). Congestive heart failure and diabetes 
are associated to the instability of the INR.  Though a predictive model has predicted, 
age more than 65 years, myocardial infarction and diabetes to have an increased 
bleeding risk. However impact of age on bleeding risk remains controversial (Ageno et 
al., 2012). Inadequate doses lead to thromboembolic events, while patients that receive      
excessive anticoagulation are at risk of bleeding (Pirmohamed, 2006, Wysowski et al., 
2007). It is known to be safe and effective when it is maintained within a narrow 
therapeutic window (Garabedian-Ruffalo et al., 1985, Wilson et al., 2003). The effective 
management of warfarin therapy requires a considerable amount of clinician time and 
resources because of the need for frequent INR laboratory tests and dosing adjustments 
(Sullivan et al., 2006, Verret et al., 2012). A study on the cost of adverse event     
showed that the mean 12 months healthcare costs for patients on warfarin were         
USD 22,507 if they had no bleeding, USD 22,824 if minor gastrointestinal          
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bleeding occurred, USD 36,571 if major gastrointestinal bleeding occurred and        
USD 42,574 if intra cranial bleeding occurred (Ghate et al., 2011). 
 
1.2.1 Monitoring Anticoagulant Intensity  
The Prothrombin Test (PT) is the most common test used to monitor VKA            
therapy. The PT responds to a reduction of three of the four vitamin K dependent      
pro-coagulant clotting factors that are reduced by warfarin at a rate proportional to     
their respective half-lives (Quick, 1935, van den Besselaar, 1991, Poller, 2004).                   
PT monitoring of VKA treatment is not standardized when expressed in seconds,          
or as a simple ratio of the patient plasma value to that of plasma from a                 
healthy control subject, or as a percentage of diluted normal plasma. A calibration 
model, which was adopted in 1982 (Kirkwood, 1983, Marlar and Gausman, 2011),                    
is now used to standardize reporting by converting PT ratio measured with the local 
thromboplastin into an INR, calculated as follows: 
INR = (patient PT/ mean normal PT) ISI or log INR = ISI (log observed PT ratio) 
Where ISI denotes the International Sensitivity Index (ISI) of the thromboplastin       
used at the local laboratory to perform PT measurement. Though not validated, INR      
is more reliable than the unconverted PT ratio (World Health Organization Expert 
Committee on Biological Standardization, 1983) and its use is thus              
recommended  during both the initiation and maintenance of VKAs. An obstacle           
to the safety and effectiveness  of warfarin therapy is the poor quality of dose 
management in routine clinical practice, as it necessitates regular and diligent 
monitoring, which  can be toilsome  for  patients  and  physicians  (Melamed et al., 
2011, Ageno et al., 2012). Patient  education, an  essential component in  
anticoagulation  management, is often neglected as  is  time  consuming for clinicians  
9 
 
and overwhelming for patients (Wofford et al., 2008). Adequate anticoagulant care with 
VKAs requires a system of patient education and careful data management to record and 
track INR  values and to ensure patients are treated with anticoagulants for an  
appropriate period of time (Ageno et al., 2012). Thus, various approaches have been 
recommended to improve anticoagulant care. These approaches which include 
anticoagulation management services, point-of-care testing, computer decision support 
systems, patient self-testing and patient self-management (Ansell et al., 2001, Testa et 
al., 2012) is shown in Table 1.1. 
 
Table 1.1 Recommended Methods of Improving Anticoagulation Care 
Care Model Operated by Operations method 
Anticoagulation 
management 
service 
Physicians or; 
Nurses/ 
pharmacists with 
physician advisory 
 
Systematically organized follow-up, 
structured education programme and 
specifically trained health personnel  
Point of care 
testing 
Nurses or; 
Pharmacists 
Point of care testing (POCT) method      
is used as 1st alternative for blood testing 
in the healthcare facility; venous blood 
sampling only conducted when INR       
is beyond the POCT sensitivity. 
 
Patient self-
testing 
Patients POCT is carried out at home by patients 
to monitor their INR. 
 
Computer 
decision support 
systems 
General 
practitioners or; 
Nurses or; 
Pharmacists 
 
A computer based dosing algorithm      
and protocol is used to manage the 
patients warfarin dosing. 
 
Patient self-
management 
Patient with 
physician/ 
pharmacist 
Selected patients are trained to self-
monitor INR using POCT, interpret      
the result and making their own      
dosing decision.   
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1.3 Anticoagulation Management Models 
Various models of care have been identified for the management of anticoagulation 
therapy (Ansell et al., 2001, Wilson et al., 2003). The primary models of   
anticoagulation therapy management are the usual medical care (UMC), the 
systematically organized anticoagulation clinic or anticoagulation management service 
(AMS) (managed individually or collaboratively by physicians, pharmacists or nurses) 
and patient  self-management (PSM) (Ansell et al., 2008b, Rudd and Dier, 2010). Usual 
medical care usually consists of venepuncture blood draw for INR and supply of 
warfarin with no organized anticoagulation management method    (Lafata et al., 2000). 
The patient self-testing management method usually warrants a home monitoring, which 
requires the patients to communicate their results to a clinic for advice on their warfarin      
dosing (Lafata et al., 2000). Whereas, anticoagulation clinics are designated to 
coordinate    and optimize the delivery of therapy, manage warfarin dosing and provide 
continuous monitoring of patients’ INR results, dietary factors, concomitant medication 
and interfering diseases (Wilson et al., 2003).  
 
1.3.1 Anticoagulation Management in Malaysia 
The Malaysian health care system consists of tax-funded and government-run     
universal services and fast growing private sector. Public health facilities provide    
about 82% of in-patient care and 35% of ambulatory care (Jaafar et al., 2013). The usual 
medical clinic (UMC) service that is used for the management of patients on warfarin   
in Malaysian government health facilities is a clinic which is run by rotational     
medical officers and physicians. Patients are seen on an appointment basis for their 
follow-up. 
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In order to provide comprehensive and focused patient care, the Pharmaceutical Service 
Division of the Ministry of Health Malaysia introduced the Medication Therapy 
Adherence Clinic (MTAC) as part of their ambulatory pharmacy services in 2004.     
The pharmacist-managed anticoagulation clinic or the Warfarin MTAC (WMTAC)    
initiated in the same year, but incorporated differently in different facilities.                    
It is operated by pharmacists who provide drug therapy monitoring and education          
to patients. It aimed to improve patients’ ability to successfully manage their disease 
condition and prevent debilitating symptoms together with reducing likelihood of 
medication errors (Ministry of Health Malaysia, 2010).  
 
1.4  Problem Statement 
In Malaysia, circulatory system diseases accounted for a total of 170, 933 or 7.55 %      
of the admissions in Malaysia in 2011, where it was within the top 10 principal     
reasons for admissions to Ministry of Health (MoH) hospitals (Abdul Rahman et al., 
2012). Diseases of the circulatory system are one of the highest causes of mortality in 
2011, 25.64 % in MoH hospitals. Latest data in a number of hospital -based studies 
indicate that VTE incidence is showing an increasing trend (Liew et al., 2012). Patients 
with VTE  also had an increased risk of subsequent AF (Hald et al., 2014).  
Prevalence of AF itself is increased by the natural history of progression with age       
and cardiovascular co-morbidities. The associated morbidity and mortality      
necessitate continued research into AF pathophysiology, pharmacologic and invasive 
therapies,   and disease management strategies to achieve and sustain improvements     
in global  AF burden (Kim, 2012). One of the goals of AF management is to prevent 
stroke  with antithrombotic therapy (Camm et al., 2010) as thromboembolic stroke is 
one  of the most feared complications associated with AF (Olesen et al., 2012). 
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The use of oral anticoagulants such as warfarin has been shown in clinical trials            
to reduce the risk of stroke by 64%; thus, warfarin therapy is widely accepted in  
patients with AF (Hart et al., 2007, Singer et al., 2008). In order to achieve maximal 
protection against stroke and to minimize bleeding complications, warfarin therapy  
must be tightly controlled and maintained within a narrow therapeutic index of 
International Normalized Ratio (INR) (Melamed et al., 2011). It is estimated that 
optimal anticoagulation could prevent 28,000 cases of stroke in the United States 
annually (Caro, 2004). The Pew Health Professions Commission of the United States of   
America reported that the systematic clinical management of patients on  
anticoagulation exclusively conducted by a pharmacist or implemented in    
collaboration with physicians or nurses has shown marked improvement (Santschi et al., 
2011). Though available literature acknowledged the superior outcomes of 
anticoagulation management services over usual medical care in terms of 
anticoagulation control  (Ansell et al., 2007b, Baker et al., 2009), caution is required due 
to the difference in  the healthcare system, prescribing pattern and anticoagulation clinic  
model (Jowett et al., 2011). However anticoagulation management often is in the      
physicians’ domain, where the choice of the management model is at                           
the physicians discretion (Ansell et al., 2007b, Baker et al., 2009). With the rising 
number of patients needing anticoagulation therapy in Malaysia, effective anticoagulant 
management is critical for achieving good clinical outcomes. Therefore there is need    
to identify efficient models of anticoagulation care from the available practices in 
Malaysia. 
World Health Organization (WHO) Programme on Cardiovascular Disease                  
has   included development of standards of care and cost-effective case management   
for cardiovascular diseases and global action to enhance capacity of countries to       
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meet the health care needs of effectively controlling the cardiovascular risks (WHO 
Programme on Cardiovascular Disease, 2014). Identifying a cost effective     
management method is affected by the variation in the population, the reference         
cost and events used, which may also vary across different countries (Jowett et al., 
2011). Thus a cost analysis is needed to identify the cost of different models of 
anticoagulation care available in Malaysia and the cost to healthcare service provider on 
whole. Consequently a cost effectiveness analysis is needed to compare the available 
models of anticoagulation care in terms of the maximum gain in patients’ health 
outcomes per unit of expenditure of the individual model. This would allow identifying 
the most cost effective system for the anticoagulation management and the control of 
cardiovascular risk factors in a Malaysian hospital. 
 
1.5 Study Objective 
The study aimed to compare the cost and efficiency of the warfarin mediation therapy 
adherence clinic (WMTAC) with usual medical clinic (UMC) in the management of 
chronic warfarin (more than six months) therapy patients in an ambulatory care setting 
in Kuala Lumpur Hospital (KLH). The efficiency is measured in terms of how the   
clinic converted its’ resources into outcomes which is the anticoagulation control.  
The specific objectives of the study are: 
i) To compare the quality, anticoagulation control between the clinics in terms of 
mean percentage of time in international normalized ratio (INR) therapeutic 
range (TTR), calculated using the Rosendaal method 
ii) To compare the costs of managing patients both in the WMTAC and UMC  
iii) To compare the cost-effectiveness of anticoagulation management between the 
WMTAC and UMC 
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CHAPTER 2:  LITERATURE REVIEW 
2.1 Evaluation of Health Services 
Health services include all services dealing with the diagnosis and treatment of     
disease, or the promotion, maintenance and restoration of health. They include     
personal and non-personal health services. Health services are the most visible   
functions of any health system, both to users and the general public. Service      
provision refers to the way inputs such as money, staff, equipment and drugs               
are combined to allow the delivery of health interventions. Improving access,     
coverage and quality of services depends on these key resources being available;          
on the way services are organized and managed, and on incentives influencing  
providers and users (World Health Organization, 2014). The Malaysian Patient Safety 
Goals stressed on clinical governance, where organizations are accountable in 
continually improving the  quality  of  the  health services  (Ministry Of Health 
Malaysia, 2013b). Thus, monitoring patients on anticoagulation, a form of health 
service, needs quality assessment and constant improvement on how the services are 
organized or managed. In spite of the many advances in the treatment available to 
chronically ill patients, these patients do not always receive optimal care (Nolte and 
McKee, 2008, Norris et al., 2003, Renders et al., 2001). Most of this is because, 
healthcare  delivery focuses on acute problems and rapid short term solutions, without 
effective treatment or the active involvement of the patients (Lenfant, 2003). In addition,      
system design has been identified as a fundamental barrier to quality improvement        
in the care delivery for the chronically ill patients (Cramm et al., 2014). The model by 
Wagner et al. (2001) on chronic care recommends quality improvement in chronic care  
delivery by providing examples of how health-care practices can shift fundamentally 
from acute and reactive care to care that is organized, structured,  planned, patient 
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centred and proactive through a combination of effective multidisciplinary team care 
and planned interactions with patients  (Cramm and Nieboer, 2013, Wagner et al., 
2001). 
Health intervention is a programme or strategy designed to produce behaviour changes 
or improve health status among individuals or an entire population. Interventions may 
include educational programmes, new or stronger policies, improvements in the 
environment, or a health promotion campaign. Interventions that include multiple 
strategies are typically the most effective in producing desired and lasting change 
(Missouri Department of Health and Senior Services, 2014). Evidence suggests          
that multi component interventions are required to change the processes and       
outcomes of chronic care delivery (Nolte and McKee 2008, Wagner, Austin 1996a, 
1996b). As such, multiple strategies are now employed in a disease management 
programme (DMP) to ensure patients benefits from the effort taken by the healthcare 
provider. These programmes typically are multidisciplinary efforts to improve the 
quality and cost effectiveness of care for defined patient populations with chronic illness          
so that the results seen in one setting can be replicated in other settings.                 
Disease management has emerged as potential strategy to enhance the quality of care 
received by patients suffering from one or more chronic conditions and cardiovascular 
diseases are the focus of many such ongoing and potential efforts. The term disease 
management programme refers to multidisciplinary efforts to improve the quality and   
cost-effectiveness of care for select patients with chronic illness. Economic pressures 
and the desire to provide better-quality care have compelled health care providers to 
examine and increasingly to employ disease management techniques (Faxon et al., 2004, 
Mosadeghrad, 2014).    
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Monitoring and evaluation of any programme or intervention is vital to             
determine whether it works, to help refine programme delivery and to provide     
evidence  for continuing  support of the programme (Global Road Safety Partnership, 
2007). Types of evaluation include process evaluation, impact assessment and outcome 
evaluation. As for impact and outcome evaluations, a quantitative method would be 
appropriate; however it would depend on the aim and available budget (Global Road 
Safety Partnership, 2007). 
In an era of fundamental concerns about the way that health care is provided to 
individuals and populations, there is a need for outcomes research to bridge the 
capabilities of the medical profession in the best interests of patients and society. 
Assumptions about what is achieved by the healthcare system should be tested by 
evidence of what actually results from the efforts (Krumholz, 2008). The themes of 
health outcomes research should be based on safety, effectiveness, equity, efficiency, 
timeliness, and patient-centeredness as key properties of high-quality health          
systems (Richardson et al., 2001). 
Innovative strategies, once found to improve patient outcomes and reduce cost should   
be appropriately adopted. Outcomes research also addresses the gap between the 
research to reduce cost; and improve outcomes and the policies that exist to facilitate 
their adoption (Krumholz, 2008). Effectiveness research is at the core of outcomes 
research. The basic research questions addresses the gap between what can be achieved 
through an intervention or policy and what is actually accomplished. Seemingly   
brilliant interventions may fall short of their promise for many reasons. Characterizing 
and addressing these gaps is an important focus of effectiveness research. In view of   
the nature of the inquiry, much of this work is best performed in observational     
studies, witnessing the experience of patients in actual practice (Krumholz, 2008). 
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There are specific difficulties in defining, developing, documenting and reproducing 
complex interventions that are subject to variations (Campbell et al., 2000a), such as the 
anticoagulation clinics as it involves various health professionals, their skill mix,   
dosing algorithm and drug related problems. In order to evaluate health interventions, a 
review of previous studies which may have provided some empirical evidence for 
example, an intervention may have been found effective for a closely related condition 
or in another country with a different organisation of health care would be useful.    
Upon review, the information would be used to identify the type of interventions,   study 
design where there is a need to assess the feasibility of the study and parameters 
measured. Trials of complex interventions are of increasing importance because of      
the drive to provide the most cost effective health care. Although these trials pose 
substantial challenges to investigators, the use of an iterative phased approach that 
harnesses qualitative and quantitative   methods should lead to improved study design, 
execution, and generalizability of results. Iterative phase is when research is conducted 
in a non-sequential phase, where an exploratory research can be carried out before or 
after an observational study (Campbell et al., 2000a). In addition to evaluating the   
performance of the indicators, government funding agencies may require additional 
information for further roll out of a programme. An economic evaluation is able to 
demonstrate   “value for money” and possible cost savings for the funding  organization 
(Global Road Safety Partnership, 2007).  
WMTAC is an anticoagulation management programme initiated by the Pharmaceutical 
Services Division, Ministry of Health as part their role in improving pharmaceutical   
care delivery. Disease management programme is identified as means of improving 
quality and efficiency of care for patients with chronic illness. Only limited number of 
published trials has documented the effectiveness of disease management, thus its     
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cost effectiveness is yet to be determined (Weingarten et al., 2002). The disease    
management programmes for anticoagulation such as the AMS in University of 
Mississippi Medical Centre has proven to have fewer subsequent hospitalizations       
and emergency department visits (Peden and Hood, 2002). 
 
2.2 Effectiveness of vitamin K antagonist 
AF is associated with a 1.5 to 1.9 fold higher risk of death, which is part due to strong 
association between AF and thromboembolic events (Wolf et al., 1991, Steinberg et al., 
2015). In a meta-analysis, the relative risk reduction with VKA was highly significant 
and amounted to 64%, corresponding to an absolute annual risk reduction in                 
all strokes of 2.7%. This reduction was similar for both primary and secondary 
prevention and for both disabling and non-disabling strokes. Many strokes occur     
when patients were not taking therapy or were sub-therapeutically anticoagulated.      
All-cause mortality was significantly reduced (26%) by adjusted-dose VKA versus 
control (placebo) (Camm et al., 2010). 
Anticoagulation effectiveness usually are measured by i) clinical outcomes -         
clinical event rates (thromboembolic and haemorrhagic events) and ii) surrogate 
outcomes - proportion of INR values within target range or percent time in therapeutic 
range (TTR) (van Walraven et al., 2009, Samsa and Matchar, 2000). The event rates 
defined as number of thromboembolism and major bleeding events per patient year 
patient    per year of follow-up are not operationalized in the same way in many studies. 
This  is simple to calculate, but biased as it depends on the tendency of the physicians to 
perform repeated tests soon after an out of range INR (Samsa and Matchar, 2000). 
Though ultimately event rates are the outcomes of interest in comparison to the 
intermediate outcomes of TTR or the proportions of in-range test, even in high risk 
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populations, significant clinical events are relatively uncommon  (Disertori et al., 2013, 
Samsa and Matchar, 2000). Sample size using event rates as the primary outcome     
need a much larger sample size than the sample size for a study using the TTR     
(Samsa and Matchar, 2000). Strong relationship between TTR and event rates are       
not only consistent with the pharmacokinetics of warfarin and consensus statements 
(Hirsh et al., 1998), but observed in large number of studies with different patient  
populations, target ranges and intensity measurement scales (Samsa and Matchar, 2000, 
Wan et al., 2008). As clinical outcomes need larger sample sizes and are not easily     
observed in trials, since it is highly coherent with TTRs, TTR should be used as the 
primary outcome while recording the clinical events as secondary outcomes    (Holbrook 
et al., 2012). 
In order to achieve maximal protection against stroke and to minimize bleeding 
complications, warfarin therapy must be tightly controlled and maintained within a 
narrow therapeutic index of INR values (Melamed et al., 2011). TTR is a standard 
quality measure of the use of warfarin (Samsa et al., 2000, Piccini et al., 2014). 
Therapeutic INR ranges  for anticoagulation are 2.0 to 3.0 for prophylaxis and treatment 
of uncomplicated  disease and 2.5 to 3.5 for patients with mechanical heart valves or 
failure with previous warfarin treatment, respectively, in accordance with the 
recommendations  of the American College of Chest Physicians Consensus Conference 
on  Antithrombotic Therapy (Hirsh et al., 2001b). Thus high anticoagulation control, 
expressed as the time spent within the therapeutic range (TTR), has a  paramount effect 
on patient outcomes, reducing stroke events which lead to a USD 2.5 billion cost 
reduction (Melamed et al., 2011) and reducing mortality rates    (Reynolds et al., 2004, 
Morgan et al., 2009). Stable INRs are defined based on consistent results  for at least 3 
months (Holbrook et al., 2012). Therapeutic INR range can be expressed in  terms of 
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percentage of time spent by individuals in the range where INR value within target/ 
therapeutic INR range can be used to assess the  thromboembolic or bleeding  risk 
(Fitzmaurice et al., 2003). The expanded therapeutic INR range is defined as the 
therapeutic range ± 0.2 INR units (Wilson et al., 2003, JHS You, 2008) and is not     
considered clinically important and would not necessarily require a dosage adjustment 
(Wilson et al., 2003). As described by Rosendaal et al.(1993) , the percentage of patient-
time      spent in the TTR and expanded therapeutic INR range is estimated using linear 
interpolation between measured INR values (Rosendaal et al., 1993). This method 
allows the determination of the optimal effects of anticoagulation (Rosendaal et al., 
1993) and takes    into account actual days in target range and allows one to calculate 
INR specific incidence rates of adverse events (Schmitt et al., 2003). A  TTR of more 
than 60% is a generally accepted threshold above which warfarin confers significant 
benefit compared with antiplatelet therapy (Connolly et al., 2008). The   association 
between TTR and clinical outcomes was confirmed in a multi-level multivariable model, 
whereas in a separate model, a 10% increase in TTR  independently predicted a 20% 
lower rate (p < 0.001) of the composite clinical outcome (e.g. stroke) among patients on 
warfarin (Van Spall et al., 2012, Apostolakis et al., 2012). Occurrence of adverse events, 
both thromboembolic and haemorrhagic events are used as a secondary outcomes 
measure (Lalonde et al., 2008).  
 
2.3 Effectiveness of Anticoagulation Management Services (AMS) 
Systematic outpatient anticoagulation services are systems of care designed to 
coordinate and optimize the delivery of anticoagulation therapy by evaluating       
patient-specific risks and benefits to determine the appropriateness of therapy; 
facilitating the management of anticoagulation dosages and prescription pick up or 
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delivery; providing ongoing education of the patient and other caregivers about  
warfarin providing ongoing education of the patient and other caregivers about   
warfarin and the importance of self-care behaviour leading to optimal outcomes; 
providing continuous systematic monitoring of patients, international normalized ratio 
results, diet, concomitant drug therapy, and disease states; and communicating with 
other healthcare practitioners involved in the care of the patient (Ansell et al., 1997, 
Chiquette et al., 1998, Bungard et al., 2009).  
Meta-analysis evaluating the service settings on anticoagulation control demonstrated 
that the AMS is associated with somewhat better outcomes than those with usual care 
(van Walraven et al., 2006, Cios et al., 2009, Baker et al., 2009).  Patients in AMS were 
spending 64 % of their treatment time in therapeutic range versus 51 % in usual care 
(Cios et al., 2009). A meta regression of six studies compared usual care patients to 
AMS, where usual care patients were spending 11% (95%CI = 2 - 20%) less time in 
therapeutic INR range (Baker et al., 2009). Many non-randomized studies have reported 
better outcomes in patients when anticoagulant therapy is managed by an AMS than 
UMC. UMC reported major haemorrhagic rates ranging from 2.8 to 8.1% per patient 
year of therapy, whereas AMS reported rates ranging from 1.4 to 3.3% (Ansell et al., 
2008a). 
A meta-analysis of 24 studies, consisting of randomized control trials (RCTs), non-
RCTs and cohort studies, a pharmacist managed AMS in comparison to clinics   
managed by other healthcare personnel, showed improved care, in terms of 
anticoagulation control, and reduced thromboembolic and haemorrhagic events. In a 
random-effect meta-analysis of randomized controlled trials, the group that received 
pharmacist-supported warfarin therapy had statistically significant improvements in    
the prevention of total bleeding [RR, 0.51; 95% confidence interval (CI) 0.28 - 0.94]. 
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However, the effects on major bleeding [RR, 0.64; 95% CI, 0.18-2.36],  
thromboembolic events [RR, 0.79; 95% CI, 0.33-1.93], mortality from all causes      
[RR, 0.93; 95% CI, 0.41-2.13] and mortality from warfarin-related causes [RR, 0.65; 
95% CI, 0.18-2.42] were not significant (Saokaew et al., 2010). Studies have shown            
that pharmacist administered anticoagulation management service is an effective 
methods  for the management of anticoagulation, in terms of greater control of INR, 
reduced thromboembolic complications and decreased length of hospital stay in 
comparison to UMC (Bungard et al., 2009, Donovan et al., 2006). However, studies 
followed -up for less than 6 month had a tendency to observe higher bleeding events and 
lower thromboembolic events. The study design of future trials were recommended to be  
6 months or more to capture all dimensions of effects on clinical outcomes (Saokaew et 
al., 2010).  
The anticoagulant control was significantly greater during AMS care compared with 
UMC; patients were in the target INR range 66.5% versus 48.8% of the time, 
respectively [95% confidence interval [CI] 13.4%–22.0%; p < 0.0001]. The relative   
risk of a thromboembolic event in UMC care was 17.6 [95% CI 6.0–51.9; p < 0.0001], 
while the relative risk of a haemorrhagic event before AMS care was 1.6 [95% CI 0.7–
3.7; p = 0.25] (Bungard et al., 2009). Another meta-analysis identified that specialty  
pharmacy clinic patients spent 71% of their treatment time in therapeutic range (Baker et 
al., 2009). A study comparing usual medical care, nurse managed clinic and pharmacist 
managed clinic identified the pharmacist managed AMS yielded the lowest rates of 
hospitalization and emergency department visits, with hospitalizations reduced by 56% 
versus nurse-managed service and 61% versus usual care (p < 0.01). In addition, the 
pharmacist-managed service incurred a lower of cost United States Dollars (USD) 141, 
277.34 in hospitalization costs and USD 10, 183.76 in emergency department visit    
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costs versus  the nurse-managed service and USD 95, 579.08 in hospitalization          
costs and USD 5, 511.21 in emergency department costs compared with the usual      
care model (Rudd and Dier, 2010).  The anticoagulation management service varied      
in terms of the health personnel managing the patients and their level of involvement 
and the management model and its’ cost (Nutescu et al., 2013). 
 
2.4 Cost of Anticoagulation Management Services 
Costs are important attributes in economic evaluations, thus appropriate costs and 
benefits must be considered. To be of maximum value, economic evaluations must       
be flexible enough to take into account local variations in resource costs and the   
estimation of cost has to be a comprehensive approach (Haycox and Walley, 1997).  
Cost definitions in the current review were from various currencies of various years. 
First, costs expressed in various currencies and base years were converted to USD in 
year 2010 using the purchasing power parity. Second, all the relevant costs were then 
converted to International Dollars (Int. $) of the same year. A summary of clinical 
outcomes and cost of anticoagulation therapy management is shown in Table 2.2. 
An earlier study of the cost of anticoagulation management compared the AMS and 
UMC in terms of adverse events noted that the savings in terms of prevention               
of subsequent morbidity was USD 211, 776 per year for all patients receiving warfarin 
in the AMS (Garabedian-Ruffalo et al., 1985), whereas another study noted that AMS in 
comparison to UMC produced a savings of USD 132, 086 annually in expenses for 
warfarin related hospitalizations and emergency department visits (Chiquette et al., 
1998). Though the costs of AMS are available based on adverse events and consultation 
cost, little available evidence identifies the details of the costing method (Aziz et al., 
2011, Bjorholt et al., 2007, Menzin et al., 2005, Anderson, 2004, Schulman et al., 2010, 
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Chan et al., 2006). One study costed only the anticoagulant medications and its’ 
dispensing fee,  INR test and the laboratory fee and clinical pharmacy specialist for the 
analysis (Anderson, 2004). Another study in the USA identified only the monitoring 
cost as     the cost of anticoagulation clinic (Menzin et al., 2005). A Swedish study 
conducted a detailed analysis of the monitoring costs, however the cost of complication 
was excluded (Bjorholt et al., 2007). Another Canadian study identified the professional 
time spent by each healthcare personnel and also provided both provider and                  
patient perspective costs, but this study avoided the costing of adverse events               
too (Schulman et al., 2010). A study in the Asian region found that the cost per patient 
per month in the pharmacist-managed group (USD 76 (SD = 95)) was lower than in the 
physician-managed group (USD 98 (SD = 158)) (p < 0.001). The limitation in this study 
was the assumption of the major component of the cost, the clinic cost, that the 
pharmacy managed clinic costs 50 % lower than the usual medical clinic (Chan et al., 
2006). Another study in the United States of America detailed the anticoagulation clinic 
cost analysis using the top down method and concluded that the hospitalization cost per 
patient per six months in the AMS was USD 401 in comparison to UMC which costs 
USD 1, 929 (Aziz et al., 2011). A newer study found that the mean 12 month costs of 
managing 136 patients were USD 18, 248 (SD = 24, 184) (Hulvershorn, 2014). 
Variations in the costing method and the type of resources used were noted in all the 
studies. Some used actual treatment cost, some used estimates of treatment and adverse 
event costs and some used only adverse event costs, whereas others used the cost of all 
the resources used for the clinic (Chan et al., 2006, Garabedian-Ruffalo et al., 1985, 
Chiquette et al., 1998, Aziz et al., 2011). A time-motion analysis would be necessary to 
validate the time estimates in a study (Anderson, 2004). 
